Gene:
FGF4
fibroblast growth factor 4

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  HSTF1; human stomach cancer, transforming factor from FGF-related oncogene; kaposi sarcoma oncogene; transforming protein KS3
Alternate Symbols:  HBGF-4; HST; HST-1; K-FGF; KFGF
PharmGKB Accession Id: PA28121

Details

Cytogenetic Location: chr11 : q13.3 - q13.3
GP mRNA Boundary: chr11 : 69587797 - 69590171
GP Gene Boundary: chr11 : 69584797 - 69600171
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

LinkOuts

Entrez Gene:
2249
OMIM:
164980
UCSC Genome Browser:
NM_002007
RefSeq RNA:
NM_002007
RefSeq Protein:
NP_001998
RefSeq DNA:
AC_000054
AC_000143
NC_000011
NT_167190
NW_001838027
NW_925106
UniProtKB:
FGF4_HUMAN (P08620)
Ensembl:
ENSG00000075388
GenAtlas:
FGF4
GeneCard:
FGF4
MutDB:
FGF4
ALFRED:
LO251330O
HuGE:
FGF4
Comparative Toxicogenomics Database:
2249
ModBase:
P08620
HumanCyc Gene:
HS01173
HGNC:
3682

Common Searches